---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-257382"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:23:51.172566+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Phathom Q3 revenue $49.5M, up 25% QoQ; net loss $30M; FY guidance raised to $170-175M

## Summary
- Net revenue of $49.5M in Q3 2025, up 25% from Q2 and from $16.4M in Q3 2024.
- Net loss narrowed to $30.0M from $85.6M in Q3 2024; non-GAAP adjusted net loss $11.2M.
- Full-year 2025 revenue guidance raised to $170-175M; expects operating profitability in 2026.
- Over 790,000 cumulative VOQUEZNA prescriptions filled; Q3 filled prescriptions up 28% QoQ.
- Appointed Sanjeev Narula as CFO/Chief Business Officer and Nancy Phelan as SVP Marketing.

## SEC filing metadata
- accession: 0001193125-25-257382
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312525257382/0001193125-25-257382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312525257382/d68071d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-257382
- JSON: https://secwatch.observer/filing/0001193125-25-257382.json
- Plain text: https://secwatch.observer/filing/0001193125-25-257382.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.